Genomill’s Bridge Capture™ Technology Featured in Elsevier News

Turku, Finland – 15.1.2026 – Genomill Health is pleased to announce that its Bridge Capture™ targeted NGS technology has been featured in a recent Elsevier press release highlighting novel liquid biopsy methods that lower barriers for efficient cancer diagnostics. The article underscores Bridge Capture’s potential to improve sensitivity, scalability, and cost-effectiveness in clinical sequencing workflows.

According to the Elsevier feature, Bridge Capture demonstrates high concordance with established commercial assays while maintaining strong performance even at reduced sequencing depth. This enables more efficient use of sequencing resources without compromising the detection of low-frequency variants—an essential requirement for liquid biopsy applications.

The article also emphasizes Bridge Capture’s flexibility and practicality. The technology supports large and customizable gene panels using a streamlined workflow that is compatible with both manual and automated laboratory setups, making it suitable for a wide range of research and clinical environments.

“Bridge Capture was designed to make high-performance liquid biopsy assays more accessible,” said Manu Tamminen, CEO and Co-Founder of Genomill Health. “Recognition by Elsevier validates our approach and reinforces our mission to deliver scalable sequencing technologies that support the future of precision oncology.”

👉 Read the full article on Elsevier news for more details

📄 Read the original article on The Journal of Molecular Diagnostics